TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Positive Phase 1a results for TRB-061 support proof of mechanism, with topline Phase 1b data in atopic dermatitis expected in mid-2027TRB-071 advancing through IND-enabling studies, with Phase 1 trial initiation expected in the first half of 2027Completed a $133.5 million initial public offering in October 2026, extending expected cash runway into the second half of 2029 SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. ("TRexBio") (NASDAQ:TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today reported financial results for the third quarter ended September 30, 2026, an